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Summary 
During T  cell activation, CD4 is intimately involved in colocalizing the T  cell receptor (TCR.) 
with  its  specific peptide  hgand bound  to  class  II molecules  of the  major histocompatibility 
complex (MHC). Previously, the  COOH-terminal residues,  Trp62/63,  which flank the im- 
munodominant epitope of hen egg lysozyme (HEL 52-61), were shown to have a profound ef- 
fect on TCR  recognition.  CD4 maintains the fidelity of this interaction when short peptides 
are used.  To determine which portion of CD4 was responsible for this effect, a series of CD4 
mutants were made and transfected into CD4 loss variants of two HEL 52-61-specific T  cell 
hybridomas. Surprisingly, some CD4 mutants that failed to interact with MHC class II mole- 
cules (D2 domain mutant) or with p56 tck (cytoplasmic-tailless mutant) restored responsiveness. 
Nevertheless, a significant reduction in association between cytoplasmic-tailless CD4 and the 
TCIL, as determined by fluorescence resonance energy transfer, was observed. Thus,  neither 
colocahzation of CD4 and the TCtL nor signal transduction via CD4 was solely responsible for 
the functional restoration of these T  cell hybridomas by wild-type CD4. However, substitution 
of the two membrane proximal domains of murine CD4 (D3 and D4) with domains from hu- 
man CD4 or intercellular adhesion molecule 1 not only abrogated its abihty to restore func- 
tion,  but  also  substantially reduced  its  abihty to  associate with  the  J"CtL.  Furthermore,  the 
mouse/human CD4 chimera had a potent dominant negative effect on T  cell function in the 
presence of equimolar concentrations of wild-type CD4. These data suggest that the D3/D4 
domains of CD4 may interact directly or indirectly with the TCtL--CD3 complex and influ- 
ence the signal transduction processes. Given the striking structural differences between CD4 
and CD8 in this region, these data define a novel and unique function for CD4. 
C 
D4 and CD8 have been shown to be critical for both 
T  cell development and peripheral activation  (1,  2). 
These coreceptors assist in the localization of the antigen- 
specific TCK with class II or I molecules of the MHC, re- 
spectively, thereby increasing the avidity of this interaction 
(3-5).  Furthermore,  both  CD4  and  CD8  are  capable  of 
transducing signals into the T  cell by virtue of their associa- 
tion with the  nonreceptor tyrosine kinase, p56  ~k (6).  De- 
spite these functional similarities, CD4 and CD8 are struc- 
turally quite distinct (7).  CD4 has four extracellular Ig-hke 
domains in  tandem,  whereas  CD8  contains  only one  Ig- 
like domain and a thin, prohne-rich, highly O-linked gly- 
cosylated stem, and is dimerized. The most divergent por- 
tions of these molecules are membrane proximal, and thus 
in  plane  with  the  TCR-CD3  complex.  Whether  these 
structural  differences represent evolutionary drift or, more 
likely, a distinguishing function for one of these molecules, 
has not been established. 
Substantial evidence that CD4 and the TCtL--CD3 com- 
plex  interact  both  physically and  functionally  now  exists 
(3-5).  Although  CD8,  which  also  associates  with  p56  ~k, 
and a cytoplasmic-tailless CD4 were each found to enhance 
the  function  of an MHC  class  II-restricted T  cell hybri- 
doma, maximal stimulation only occurred with the intact 
CD4 molecule (8).  Thus,  CD4 and the TCtL have to in- 
teract with the same MHC molecule, and at least one site 
of CD4-TCR  interaction  occurs  intracellularly.  Fluores- 
cence resonance energy transfer (FRET)  1 has so far provided 
the  best  evidence  for  direct  physical  association  (9-11). 
While both murine (m) and human (h) CD4 were found to 
interact with the TCtL-CD3 complex, this ability was ab- 
1Abbreviations used in  this paper: FILET, fluorescence resonance energy 
transfer; h, human; HEL, hen egg lysozyme;  ICAM-1, intercellular  adhe- 
sion molecule 1; m, routine; tTA, tetracycline-controlled  transactivator. 
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appears to perform important kinase-independent functions 
during T  cell activation, it may act as an adapter between 
CD4 and the TCR-CD3  complex (12). 
The possibility that CD4--TCR interaction has an effect on 
T  cell function was recently assessed in a series of hen  egg 
lysozyme (HEL) 52-61--specific T  cell hybridomas (13, 14). 
While  CD4 +  hybridomas responded  to  any peptide con- 
taming this epitope regardless of  length or NH2- and COOH- 
terminal composition,  CD4-  variants could only respond 
to  peptides  containing  two  additional  COOH-terminal 
tryptophans at positions 62 and 63.  Thus, the fine specific- 
ity of MHC-peptide recognition by the TCR  was dramat- 
ically affected by CD4 and by the COOH-terminal peptide 
composition.  Interestingly,  peptides  that  failed  to  induce 
IL-2 secretion in  the  CD4-  variants nevertheless induced 
strong tyrosine phosphorylation of CD3~  (15). Thus, TCR 
recognition of certain peptides failed to induce the full ar- 
ray of signals required for IL-2 secretion, and CD4 restored 
this defect. This partial signaling was also seen in other sys- 
tems using antagonist peptides (16,  17). 
The  aim  of the  present  study was  to  determine  which 
portion and function of CD4 was responsible for restoring 
T  cell  reactivity in  CD4-  T  cell  hybridomas.  The  distal 
D1/D2  domains,  which  bind  to  MHC  class II molecules 
(18),  or the cytoplasmic tail, which transduces signals into 
the T  cell via p56 lck (6),  are possible candidates. However, 
the proximity of the membrane proximal D3/D4  domains 
to the TCR-CD3  complex, together with data suggesting 
that CD4  can interact with this complex, raised the possi- 
bility that these domains may be involved. 
Materials and Methods 
Construction of CD4 Mutants.  The mutant CD4 molecules made 
are detailed in Fig. 1.  The mCD4.ACY construct was made by 
substituting Glnl03 (19) for a stop codon (T for C  at bp  1312) 
using site-directed mutagenesis (Promega Corp., Madison, WI). 
This  leads  to  a  cytoplasmic  tail  of  only  five  anaino  acids 
(RCRHN),  which is required to retain CD4 in the membrane. 
The mutant mCD4.MM4 is a MHC contact mutant that has had 
the  D2-A  strand  mutated  (residues  101-107:  KVTFSPG  to 
GLTTTTT;  kindly provided by Dan Littman, Howard Hughes 
Medical Institute  [HHMI],  New York University, New York) 
(12).  The chimera, mCD4.MM4/ACY was made by subcloning 
the 5' terminal half of pSM-L3T4-MM4 into mCD4.ACY.pA1- 
ter at the unique SexA1 restriction site. 
The  remaining  constructs  involved  substituting  the  mCD4 
D3/D4 domains with segments from either hCD4, human inter- 
cellular adhesion molecule 1 (hlCAM-1), or mCD8  (Fig.  I). A 
mCD4  template  was  first  constructed  using  site-directed mu- 
tagenesis by inserting restriction enzyme sites at the junction of 
these domains (mCD4.mutD3/D4),  and then generating the re- 
quired donor fragments by recombinant PCR using primers with 
comparable  restriction  sites.  The  strategy  for  producing  these 
constructs took advantage of the numerous blunt cutting restric- 
tion enzymes currently available. All mutations gave rise to blunt 
fragments between the second and third base pair in a codon to 
ensure constructs remained in frame (division at this point was cho- 
sen as it did not give rise to any unwanted amino acid mutations). 
These mutations were made in murine CD4 by site-directed mu- 
tagenesis and the resultant construct, mCD4.mutD3/D4, was used 
as a recipient for mutant fragments produced by PCR. The divi- 
sion between the D2 and D3 domains occurred within the con- 
served Phe186 (bp 660-665;  19), which is the second amino acid 
after the proposed D2/D3 junction, by insertion ofa HpaI site. The 
division between D4 and TM occurred within Glu371  (bp 1203- 
1208),  which is the penultimate amino acid before the D4/TM 
junction, by insertion of a SmaI site.  Information regarding the 
junctions between mCD4,  hCD4,  and hlCAM-1  domains was 
provided by Steven Harrison (personal communication, Harvard 
University, Cambridge, MA). 
The following domains were produced by PCR: hCD4.D3/D4 
domains, HpaI site to  cleave Phe181  (bp 684-689;  20),  second 
amino acid after D2/D3 junction, and Sinai site to cleave Pro370 
(bp 1260-1265), last amino acid before the D4/TM junction (last 
nine COOH-terminal amino acids in hCD4.D4 domain contains 
three prolines that may be structurally important, so all three were 
retained); hlCAM1.D3/D4  domains, Hpal site to cleave Ala189 
(bp 702-707;  21),  last amino acid before D2/D3 junction,  and 
PmlI site to cleave Pro369  (bp 1242-1247)  between the D4 and 
D5 domains; hlCAM1.D4/D5 domains, HpaI site to cleave Pro287 
(bp 975-980), last amino acid before D3/D4 junction, and PmlI 
site to cleave Glu453 (bp 1494-1499), last amino acid before the 
D5/TM junction; hlCAM1.D4-CY  domains  (includes the  I)4, 
D5, TM, and CY domains), HpaI site to cleave Pro287 (bp 975- 
980),  last amino acid before D3/D4 junction, and EcoR1 site (bp 
1686-1691)  introduced  12 bp after the stop codon at bp  1674; 
and mCD8  stem, HpaI site to cleave Ser124  (bp 462-467)  (22) 
and NruI  site to  cleave Arg154  (bp 552-557).  This latter con- 
' struct also included a substitution of Cys151  for Ser (T544A)  as 
this prevented intracellular retention (Vignali,  D., and B.  Chang, 
unpublished results).  In producing this construct it was assumed 
that CD4 and CD8  extend the same distance from the cell sur- 
face,  thus  the  CD8  stem  is  analogous  to  three  CD4  domains. 
Therefore, two thirds of the stem was used starting from the base 
of the Ig-like domain of CD8. 
All PCR reactions were performed with pfu DNA polymerase 
which has 3'-5' exonuclease capability, thus substantially reduc- 
ing base error incorporation (Stratagene Inc., La Jolla, CA; used 
according to the manufacturer's instructions with the addition of 
10% DMSO). PCR products were first blunt end subcloned into 
pGEM-7Zf(+) for complete bi-directional sequencing (Sequenase; 
United  States  Biochemical  Corp.,  Cleveland,  OH).  After  se- 
quence verification, the fragments were excised with the restric- 
tion enzymes encoded within the PCR primers and ligated into 
mCD4.mutD3/D4 to produce the complete construct. The cor- 
rect junctions were verified by DNA sequencing. Recombinant 
PCR and other standard molecular biology techniques were em- 
ployed. 
All constructs were subsequently subcloned into a eukaryotic ex- 
pression vector containing the  human  [3-actin  promoter,  SV40 
poly A  and a  neomycin resistance cassette  (pHBApr-lneo;  23). 
Some mutants were subcloned into a new vector, pHf3Apr-Ilpuro, 
which differs from pH[3Apr-lneo in possessing a puromycin resis- 
tance cassette  and expanded polylinker. Efficient surface  expres- 
sion of the constructs was  tested using transient Cos transfection 
and immunocytology, before transfection of T  cell hybridomas. 
mAbs.  A panel of mAbs was obtained and used to stain the 
transfectants for subsequent analysis by flow cytometry. The anti- 
mCD4 mAhs and the domains they recognize are indicated (see 
Fig. 2). They are as follows (all rat IgG unless stated): GK1.5 (24), 
YTS 191.1, and YTA 3. ] (25) were already present in this labora- 
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vided by Kathryn Wood (Oxford University, Oxford, England); 
YT4.1 and YT4.2 (27) by CharlesJaneway (Yale University School 
of Medicine, New Haven, CT); RL172.4 (28; IgM) by Johnathan 
Sprent (Scripps Research Institute, La Jolla, CA); and 2B6  (29; 
IgM) by Ethan Shevach (National Institutes of Health, Bethesda, 
MD). hCD4 mAbs were as follows (all mouse IgG) and domain(s) 
recognized are in square brackets: OKT4 was already present in 
this laboratory [D4];  Q425  [193] (30) was kindly provided by Pe- 
ter Kwong (Columbia University, New York); L120  [I)4]  (30) 
by David Buck  (Becton Dickinson &  Co.,  San Jose,  CA); and 
MT429  [D3-4]  by Peter Rieber (Munich University, Munich, 
Germany).  hlCAM-1  mAbs  were  as  follows  (all  mouse  IgG): 
P3.58-BA-19 [D1], P3.58a [D3-4], P3.58-BA-14 [D4-5], P3.58- 
BA-23  [D4-5],  P3.58-BA-3  [D5],  and P3.58-BA-11  [D5]  (31, 
32) were kindly provided by Judy Johnson (Munich University), 
and CL203-4  [D2  or 4]  (33)  by Soldano  Ferrone  (New York 
Medical College, Valhalla, NY). 
Murine T Cell Hybridomas and Transfectants.  CD4 + and CD4- 
variants of 3A9 (P4 and N49, where P denoted CD4 + and N  de- 
notes CD4-), and A2.2B2 (P2, N22) were isolated as previously de- 
scribed (13,  34). Both are HEL 52-61  specific and restricted by 
H-2A  k. Peptides used were HEL 48-61WW (DGSTDYGILQIN- 
SRWW) and HEL 48-61FF (DGSTDYGILQINSRFF). BW.D10- 
TCR(9.3).Null(115.3)  (BW.D10)  and  BW.D10-TCR(9.3).CD4 
(8.12).Null(5.3) (BW.D10.mCD4)  are BW5147 transfectants ex- 
pressing the D10 TCR +/-  CD45.Null and recognize the con- 
albumin peptide (HRGAIEWEGIESG) in the context of H-2A  k 
(kindly provided by Dave Leitenberg and Kim Bottomly, HHMI, 
Yale University School of  Medicine) (35). 171.3 [herein termed 171] 
(CD4-),  171.mCD4,  171.hCD4,  and 171.MM4 recognize HEL 
74-88  (NLANIPASALLSSDI) in the  context of H-2A  b (kindly 
provided by  Mark  Hill and Dan  Littman,  HHMI,  New  York 
University) (12). Crude peptides were obtained from Chiron Mimo- 
topes, purified to 95% by reversed-phase HPLC, and analyzed for 
integrity, composition, and concentration using mass spectrome- 
try and quantitative amino acid analysis as previously described (36). 
The 3A9 and A2.2B2 CD4- hybridomas were transfected with 
the constructs detailed above, hCD4-pH[3Apr-lne0, and mCD8- 
pH~3Apr-lneo  (provided  by Jane  Parnes,  Stanford  University, 
Stanford, CA)  (20  mg of PvuI linearized DNA by electropora- 
tion; Gene Pulser, Bio-Rad Laboratories, Hercules, CA) and se- 
lected  with  G418  (GIBCO  BRL,  Gaithersburg,  MD).  The 
BW.D10  and  171  hybridomas were transfected with constructs 
subcloned into pH[3Apr-Ilpuro  and selected with puromycin. Re- 
sistant transfectants were cloned by FACS  |  Cells were double la- 
beled with  GK1.5  biotin  (anti-CD4)  followed by streptavidln- 
phycoerythrin  (Caltag Laboratories, South  San  Francisco,  CA) 
and anti-CD3-FITC (GIBCO BRL). Positive cells with equiva- 
lent TCR-CD3  and CD4  expression as the parental CD4 + hy- 
bridoma were sorted at one cell per well (via EPICS 750  Series 
with autoclone attachment, Coulter, Hialeah, FL, or FACS Star 
Plus  |  Becton Dickinson & Co.). After 2 wk, ,'o24 clones were 
tested for CD4 and TCR, and selected clones for equivalence of 
CD2,  LFA-1,  CD45,  CD5,  LFA-1,  and  CD28  expression by 
flow cytometry (FACScan  |  Becton Dickinson & Co.). At least 
six of these were then tested for their equivalence of sensitivity to 
immobilized anti-TCR (H57.157). 
Tetracycline-regulated  Expression of the m/hCD4 Chimera.  lrdhCD4 
was expressed under the regulation ofa tetR/VP16 fusion protein 
that  acts  as a potent tetracycline-controlled transactivator (tTA) 
when bound to the tetO upstream of a TATA box. To establish 
the system used in this study, two new plasrnids were constructed 
from those originally developed by Gossen and Bujard (37). First, 
a new reporter plasmid, UHD.2neo, was made that contains a neo- 
mycin resistance gene and a new polylinker cassette.  The starting 
plasmid was pUHD.10S  (kindly provided by Maarten Fornerod 
and Gerard Grosveld, St. Jude Children's Research Hospital) which 
differs  from the original vector in containing a 5'  SV40 double 
stop and a  different plasmid backbone  (38).  A  neomycin resis- 
tance cassette,  containing a SV40 early promoter and poly A site, 
was subcloned from pMAMneo (Clontech, Palo Alto, CA) into a 
unique  NgoMI  site  in  the  opposite orientation and  3'  of the 
7tetO-TATA-SV40 poly A cassette. Finally, a new polylinker was 
inserted  by  ligating two  94-bp  annealed  oligonucleotides be- 
tween the EcoRI and XbaI sites. This contained the following el- 
ements and unique restriction sites: downstream T7 promoter-- 
EcoRV--EcoRI--XbaI--SalI--MscI--upstream SP6 promoter. 
For this  study,  the  m/hCD4  chimera  was  subcloned into  the 
EcoRI/SalI sites to create m/hCD4.UHD.2neo. 
The second plasmid, UHD-Tet/VP16puro, involved a modifi- 
cation of the original construct containing the tTA driven by a 
constitutive cytomegalovirus promoter. We and others (39) have 
found that the majority of transfectants fail to  express the tTA, 
possibly due to the toxic effects  of overexpression. To obtain a 
more sensitive and regulated system, a new plasmid was devel- 
oped  following  an  idea  originally proposed  by  David  Schatz 
(HHMI, Yale University School of Medicine; 39)  in which the 
tTA regulates its own expression by using the same 7tetO-TATA 
promoter system that drives expression of the reporter in UHD.2 neo. 
First, an EcoRI/HindlII fragment from pUHD15-1  (37) contain- 
ing the tTA construct was subcloned into pPGKpurobpA (kindly 
provided by Ramiro Ramirez-Solis, Baylor College of Medicine, 
Houston,  TX)  5'  to a puromycin resistance gene driven by the 
phosphoglycerate kinase promoter. Then, the tTA/PGK promoter/ 
puromycin cassette  was subcloned into the EcoRI/XbaI sites of 
UHD10S, such that the 7tetO-TATA promoter drives expression 
of the tTA, and the SV40 poly A site in UHD10S is placed 3' to 
the puromycin gene. This generates the new plasmid UHD-Tet/ 
VP16puro. 
The original wild-type mCD4-positive 3A9 hybridoma (kindly 
provided by Paul Allen, Washington University, St. Louis, MO) 
was  first  transfected  by  electroporation  with  the  UHD-Tet/ 
VP16puro  plasmid.  Puromycin-resistant clones  were  tested  for 
regulated expression of the tTA by PCR.  One clone, 3A9.V12 
[herein referred to  as 3A9.V], was chosen and transfected with 
m/hCD4.UHD.2neo.  Several clones were tested by flow cytome- 
try with Q425, which recognizes the D3 domain of human CD4, 
and in antigen presentation assays as described below. Transfec- 
tants were cultured for 24  h  before the  experiment with 0.1-1 
IxM  tetracycline (LDs0, 0.5  raM)  which  was  found  to  silence 
transcription of the m/hCD4 chimera. 
Coimmunoprecipitation of CD4 and p56  ~k.  Approximately 107 cells 
were lysed with 500  p,l lysis buffer (1% NP-40  [Fluka Chemical 
Corp., Ronkonkoma, NY], 20 mM Tris/HC1, pH 7.4, 150 mM 
NaC1,  5% glycerol, and enzyme inhibitors [2 mM Pefablock from 
Centerchem, Stamford, CT,  25  IxM aprotinin, and 25  IxM leu- 
peptin]). Lysates were left at 4~  for 1 h, spun for 15 rain in a mi- 
crocentrifuge and precleared twice with 50 Ixl of a 10% suspen- 
sion of Pansorbin (Calbiochem-Novabiochem Corp., San Diego, 
CA).  Protein  G--Sepharose beads  (Pharmacia,  Piscataway,  NJ) 
were precoated for 2 h at 4~  with either GK1.5 (anti-mCD4) or 
53.6.7  (anti-mCD8).  Beads  (25  p,1) were  added  to  lysate and 
rocked at 4~  overnight. Samples were washed twice with lysis 
buffer and once in modified lysis buffer with 0.1%  NP-40  and 
without glycerol. Eluted proteins were resolved on a  12% SDS- 
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chef & Schueli,  Inc., Keene, Nil). Blots were blocked with 5% 
nonfat dry milk in TBS-T (0.2% Tween 20,  10 mM Tris/HCl, 
pH 8, 150 mM NaC1) at 4~  overnight, p56  t'k was detected with 
a  rabbit  polyclonal antisera  (from Joseph  Bolen,  Bristol-Myers 
Squibb,  Princeton, NJ), followed by a 1:40,000 dilution of goat 
anti-rabbit horseradish  peroxidase,  and developed using enhanced 
chemiluminescence (Amersham,  Arlington Heights, IL). 
Antigen Presentation  Assays.  Assays  were performed essentially 
as described  elsewhere  (34, 40). Briefly,  T  cell variants  (5 ￿  104; 
100 p-l) were cultured with 2.5 ￿  104 (100 p~l) LK35.2 (murine B 
cell lymphoma; H-2A  ka) in flat-bottom, 96-well microtiter plates 
with synthetic peptides  or HEL (Sigma Chemical Co., St. Louis, 
MO) at the concentrations indicated.  Supernatants  (50 p,1) were 
removed after 24 h for estimation of IL-2 secretion by culturing 
with  the  IL-2-dependent T  cell  line  CTLL-2.  Two  protocols 
were used:  (a) 5  ￿  104 cells in 50 ILl were used and proliferation 
was  determined  by  an  MTT  assay according to  the  manufac- 
turer's instructions  (Promega Corp.) (see Fig. 4); or (b) 104 cells in 
100  ~1  were  used and proliferation was determined  by pulsing 
with [3H]thymidine as previously described  (34) (see Figs. 5 and 
6). IL-2 concentration was determined by using routine recombi- 
nant IL-2 (Genzyme Corp., Cambridge, MA) as a standard.  ECs0 
values were determined by titrating peptides  10-fold from 10 p-M 
to 100 pM, calculating  the number oflL-2 units for each dilution 
from a recombinant IL-2 standard,  and then evaluating the con- 
centration ofpeptide required to give 50% stimulation. 
FRET.  Hybridomas (106) in 1LPMI 1640 plus 10% FCS were 
stained with 5 p-g/ml each of F23.1-FITC (anti-TCR-V[38) and 
GK1.5-tetramethylrhodamine isothiocyanate on ice for 30 rain. 
Cells were then washed and analyzed as previously described  (9). 
Results 
Production and  Characterization of Murine  CD4  Mutants. 
A  series of murine  CD4 mutants was constructed  (Fig.  1). 
They consisted of CD4 molecules that either lacked a cyto- 
plasmic  tail  (mCD4.ACY),  possessed  mutations  in  the  A 
strand of the D2 domain, which results in an abrogation of 
MHC  class  II binding (mCD4.MM4)  (12),  or a combina- 
tion  of the  two  mutations  (mCD4.MM4-ACY).  In addi- 
tion,  the  membrane  proximal  D3/D4  domains  of murine 
CD4 were replaced in five mutants with either the homol- 
ogous domains from human  CD4  (hCD4),  domains from 
the  Ig supergene  family relative,  hlCAM-1,  or part of the 
membrane  proximal  stemlike  structure  of murine  CD8 
(mCD8).  One of these  also possessed the hlCAM-1  trans- 
membrane and cytoplasmic segments. 
These  mutants  were  transfected  into  CD4  loss  variants 
derived from 3A9 and A2.2B2, two H-2Ak-restricted, HEL 
52-61-specific T  cell hybridomas (13,  15). In some experi- 
ments,  certain  mutants  were  transfected  into  two  further 
CD4 loss variants,  BW.D10,  which recognizes a  conalbu- 
rain  peptide  in  the  context  of  H-2A  k  (35),  and  171.3 
[herein  termed  171],  which recognizes HEL 74-88 in the 
context of H-2A  b (12).  Stable transfectants were cloned by 
single cell sorting to derive cells that had comparable CD4 
and TCtL-CD3 expression as the parental CD4 + T  cell hy- 
bridoma.  The structural integrity of the mutants was tested 
in two ways: first by flow cytometry using a panel ofmAbs, 
Figure  1.  Diagrammatic representation of the CD4  mutants used in 
these studies. (D1-D5) Extracellular domains of CD4 or ICAM-1; (TM) 
transmembrane domain; (MM4) mCD4 containing a mutation in the D2 
domain resulting in  failure to  bind to  MHC  class II molecules (12); 
(/iCY) cytoplasmic  domain deleted. 
and second by assessing the ability  of the  mutants  to bind 
the src-family tyrosine kinase, p56  t'k. 
Epitope analysis of the CD4 mutants with a panel ofanti- 
CD4  mAbs demonstrated  that  there  were  no  gross  struc- 
tural perturbations (Fig. 2). Most of the mAbs gave binding 
patterns  that could have been predicted from the  domains 
they recognized (41). Thus, GK1.5 and YT4.1, which rec- 
ognize distinct  epitopes  in the D1  domain,  recognized all 
the mutants whereas YTA3.1 and 2B6, which recognize epi- 
topes in the murine D3/D4 domains, only recognized mole- 
cules that possess these domains. However, two exceptions 
were  noted:  KT9  and YT4.2,  antibodies  specific  for epi- 
topes in the D1/D2 domains, stained all the mutants except 
those that included domains from hICAM-1. This could be 
due to either a conformational distortion  of these,  but not 
other mAb epitopes,  or steric  hindrance  of these  epitopes 
caused  either  by  the  distinct  positioning  of the  ICAM-1 
domain loops or additional  glycosylation sites  (mCD4 D3 
has one site, hICAM-1 D3 and D4 have two sites  each) (19, 
21). The two instances of partial staining with RL172.4 are 
not thought to be significant as they involved two different 
constructs  and were with  transfectants  that had the lowest 
levels  of GK1.5  staining.  The  mCD4.MM4  mutant  was 
recognized by all the anti-mCD4 mAbs except YT4.2 (data 
not  shown),  suggesting  that  this  antibody  binds  to  an 
epitope  that  encompasses  residues  on  the  A  strand  of the 
D2 domain. 
The T  cell transfectants were also tested with mAbs that 
recognize either hICAM-1 or hCD4 (data not shown). All 
but one of the seven anti-hICAM-1  rnAbs recognized the 
CD4  mutants  as  expected.  P3.58a,  which  is  reported  to 
2100  Interaction Between CD4 and the TCR-CD3 Complex Figure 2.  Analysis  of CD4 mutant molecules  by flow cytometry. Epitopes were as deduced in reference 41 and by the data presented here (GK, RL, 
and YT are separate epitopes in D 1 named after the principle  antibody).  Data are representative  of two separate experiments. GK1.5 data are represented 
as mean log fluorescence. The remaining  data were normalized  to GKI.5 data of each cell to account for variable  cell surface expression and the intensity 
of each mAb with 3A9.P4/A2.2B2.P2 to 1.00. Data in (solid boxes) >0.6; (stippled  boxes) 0.2-0.6; and (open boxes) <0.1.  Controls stained with GK1.5 
were: 3A9.P4, 2,188; 3A9.N49, 5; A2.2B2.P2, 1,163; A2.2B2.N22, 8: negative  control, 4. 
recognize an epitope  in the  D3-4  domains of hlCAM-1 
(32), failed to recognize hlCAM.D3/4. The reason for this 
is unclear but could be due to a defect in the m4/IC.D3/4 
mutant. The binding of all four anti-hCD4 D3/D4 domain 
mAbs to the m/hCD4 mutant and hCD4 transfectants was 
identical. 
The mutant molecules were  also tested for their ability 
to bind p56  Ick, which intrinsically associates with the cyto- 
plasmic tail of CD4  (6).  All the  constructs,  except  as  ex- 
pected  mCD4.ACY  and mCD4/hICAM.D4-CY, bound 
to p56  ~k with comparable efficiency (Fig. 3). 
The Influence of the D3 /D4 Domains of CD4 on TCR Rec- 
ognition.  The recognition of HEL 52-61-derived peptides 
that lack the  two  COOH-terrninal adjacent tryptophanes 
(Trp62/63;WW) was  previously shown  to  be  totally de- 
pendent on the presence of CD4, whereas the presence of 
these residues negated the requirement for CD4 (15). Pep- 
tides in which these residues were substituted with phenyl- 
alanine  (Phe62/63;FF)  failed  to  stimulate  CD4-  T  cell 
hybridomas. The effect of the CD4 mutants on T  cell func- 
tion was  assessed  by comparing the  response  of 3A9.N49 
(CD4-)  transfectants  to  HEL  48-61WW  and  48-61FF 
(Figs. 4  and 5).  Ligation by immobilized anti-TCR mAbs 
was used as a control. As expected, all the transfectants re- 
sponded to  the  anti-TCR mAb and HEL 48-61WW, al- 
beit with some variation. However, their response to HEL 
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48-61FF was dramatically different. Despite several reports 
demonstrating a substantial loss of function in the absence 
ofp56e~CD4 interaction (8,  11,  12, 42), the mCD4.ACY 
transfectants were  as  responsive to  HEL  48-61FF  as  the 
wild-type transfectant. Binding of CD4  to  MHC  class  II 
molecules has also been shown to be critical for the function 
of some T  cell hybridomas (12). However, the response of the 
mCD4.MM4 transfectant of 3A9 cells to HEL 48-61FF was 
Figure 3.  Ability  of CD4 mutants to bind p56  t~k. Anti-CD8 or anti- 
CD4 immunoprecipitates  from the indicated  transfectants  were probed by 
Western blot for the coassociation of p56  k*.  (CD4  + and CD4-) Sorted 
3A9 variants; (CD4.  W'I)  3A9 CD4 loss variant transfected with wild- 
type mCD4; (D3-DS) extracellular  domains oflCAM-1; (IG hlCAM1; 
and (ACY) cytoplasmic domain deleted. Data are representative of three 
experiments. mCD4  + 
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Figure 4.  Effect  of CD4 mutants on T cell responses to peptide and anti-TCR antibody. Peptides (102-10  -4 ~M) and anti-TCP,, antibody (H57.157; 
104 to 10 -2 nM) were titrated and the data presented as ECs0, which is the concentration that gives 50% stimulation. Bar charts (right) depict the cell sur- 
face expression ofmCD4 determined by flow cytometry using GK1.5. (NA) Not applicable. Data are representative of  five experiments performed in du- 
plicate. (m4/IC) mCD4/hlCAM. 
reduced by only one log10, despite the complete inability of 
this mutant to restore any function in the 171  and BW.D10 
T  cell hybridomas  (Fig.  5).  Thus,  the  function of CD4 in 
the recognition of HEL 48-61FF by 3A9 was distinct from 
its ability to bind MHC  class II molecules or p56 ~k, as nei- 
ther  of these  interactions  alone  was  critical.  However,  if 
these two mutations were combined (mCD4.MM4-ACY), 
no restoration of function was observed. Thus at least one, 
but not both,  of these sites  of interaction was required  for 
the  function  of CD4  in  3A9  cells.  Furthermore,  mCD8 
failed to restore reactivity to HEL 48-61FF; thus,  increas- 
ing cell-cell adhesion in this way was insufficient to restore 
function. 
Surprisingly,  any mutant in which the D3/D4  domains 
of mCD4 were replaced with domains from hCD4, mCD8, 
or hlCAM-1  failed  to  restore  responsiveness  to  HEL 48- 
61FF, implying a unique role for this region of CD4 (Figs. 
4 and 5). Even the homologous substitution of domains be- 
tween  murine  and  human  CD4  abrogated  function  in  all 
the hybridomas tested.  Possibly all  CD4-dependent  hybri- 
domas  require  the  D3/D4  domains  for  function,  even 
though  their  dependence  on CD4  interaction  with  p56  tck 
and/or MHC  class II molecules may vary. 
hCD4 can functionally replace mCD4 both in vitro and 
in vivo (42-45).  In 3A9 transfectants, hCD4 was reproduc- 
ibly one log10 less efficient than mCD4 at restoring reactiv- 
it-/to HEL 48-61FF, despite an equivalence of function in 
171  transfectants  (Fig. 5). This difference has also been ob- 
served with another hybridoma, A167 (34).  Although hCD4 
did not fully replace  mCD4 in 3A9, it was far better than 
the m/hCD4 chimera. This discrepancy could be explained 
on the basis  of affinity or structural integrity. While hCD4 
has an affinity of 3  ￿  106 M -1 for HLA-DR4 (46), mCD4 
has  an  affinity  of ~<104 M -1  for H-2A/E  d  (47).  Further- 
more, hCD4 appears to have significantly higher affinity for 
H-2A  d than mCD4 (44). Thus, the m/hCD4  chimera may 
have a lower affinity for H-2A  k than  hCD4.  Second,  the 
construction of this mutant may have affected some subtle 
structural feature and its  ability to interact with the TCR- 
CD3  complex, MHC  class  II molecules,  and/or p56/ok for 
signal transduction. 
The m/hCD4  Chimera Can Act as a Potent Dominant Neg- 
ative.  Neither the interaction of CD4 with MHC  class II 
molecules  nor that  with  p56 lck was  totally  essential  for its 
function in 3A9; one or the other appears to suffice for at 
least partial activity. The failure of the m/hCD4 chimera to 
function at all was anomalous and it was, therefore, impor- 
tant  to demonstrate  that  the  m/hCD4  chimera was struc- 
turally  intact.  Were  it able  to interact  with  MHC  class  II 
molecules and p56 lck with an efficiency comparable to wild- 
type  CD4,  but  unable  to  interact  with  the  TCR-CD3 
complex, it would actively compete with wild-type CD4; 
50% inhibition  might be seen when the mutant and wild- 
type  CD4 are present  in equal  amounts.  To  evaluate  this 
hypothesis,  the  m/hCD4  chimera  was  expressed  in  the 
wild-type CD4 + 3A9 T  cell hybridoma under the regula- 
tion of tTA.  Strikingly,  the  m/hCD4  chimera  completely 
out competed wild-type CD4 (Fig. 6 A) even though both 
were present  at comparable levels  (Fig.  6  B).  In the pres- 
ence  of tetracycline,  the  expression  of the  m/hCD4  con- 
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Figure 5.  Comparison of mutant CD4 function in three different hybridomas. A series of CD4 mutants were transfected into three different CD4- T 
cell hybridomas  specific for the antigens indicated above. (3A9) Restricted by H-2A  k. (BW.D  10) A BW5147 transfectant expressing the D 10 TCR and 
CD45.Null (35) is restricted by H-2A  k and specific for a conalbumin peptide (HRGAIEWEGIESG). (171) (12) Restricted by H-2A  b and specific for 
HEL 74-88 (NLANIPASALLSSDI).  For explanation of the CD4 mutants, see legends to Figs. 1 and 4. For the 3A9 transfectants, mCD4.WT serves as 
the control for m/hCD4 and hCD4 which all express comparable levels of CD4, whereas mCD4.WT hi is the control for mCD4.MM4, mCD4.Acy, 
and mCD4.MM4-ACy.  All transfectants of a given hybridoma responded comparably to immobilized anti-TCR antibody. Data are representative of 
three to five independent experiments. 
struct was abrogated and the response of 3A9 to HEL 48- 
61  restored to wild-type levels. These data strongly suggest 
that  the  m/hCD4  chimera  is  fully  capable  of binding  to 
both MHC  class II molecules and p56  tck in a manner func- 
tionally comparable to wild-type CD4. Thus, the m/hCD4 
chimera acts as a potent dominant negative in the presence 
of wild-type CD4. 
Reduced Physical Interaction between the m/hCD4  Chimera 
and the TCR-CD3  Complex.  Since  the  D3/D4  domains 
of CD4 can influence TCR recognition, the possibility that 
these  domains  may directly  interact  with  the  TCR-CD3 
complex was next explored. FRET, in which molecular as- 
sociation is  determined  by energy transfer from a  FITC- 
labeled  antibody bound  to  the  TCR-CD3  complex to  a 
TRITC-bound  antibody attached to CD4,  was employed 
(9,  11).  As  expected,  the  wild-type  CD4  transfectant  of 
3A9.N49 displayed good levels of energy transfer, whereas 
essentially  insi~.ificant levels were observed with the mCD4/ 
hlCAM.D4-CY  transfectant  (Fig.  7).  This  construct lacks 
both  the  D3/D4  domains  and  cytoplasmic tail  of mCD4. 
No energy transfer was observed with the mCD4/8  trans- 
fectant  even  though  it  retains  the  CD4  cytoplasmic  do- 
main.  As  this  mutant  has  had  the  two  bulky  Ig-like  do- 
mains of CD4 replaced with part of the stemlike  structure 
from CD8,  which  is  t,ormaUy  expressed  as  a  dimer,  it  is 
possible  that  the juxtaposition  of the  mCD4  D1  domain 
has been altered so that energy transfer cannot occur or that 
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dimerization of the CD8 stem, which cannot occur in this 
mutant,  is  required  for  structural  integrity.  Although  the 
mCD4.ACY transfectant  showed reduced energy transfer, 
this level was significantly above background levels  (com- 
pared  with  mCD4/hlCAM.D4-CY),  implying  the  pres- 
ence of another interaction site. Similarly, only half the en- 
ergy transfer observed with the wild-type transfectant was 
seen  in hybridomas expressing m/hCD4.  Thus,  the inter- 
action of CD4 with the TCR-CD3  complex appears to in- 
volve both  the  D3/D4  domains  and  the  cytoplasmic tail, 
although only the former is functionally significant. 
Discussion 
There  is  now substantial  evidence  that  CD4  physically 
interacts with the TCR-CD3  complex (3-5). This colocal- 
ization  may be  required  to  bring  the  CD4-associated  ty- 
rosine kinase,  p56 tck, into close proximity to targets within 
the TCR-CD3  complex or associated molecules (6). How- 
ever,  the  responsiveness  of a  CD4-negative  T  cell hybri- 
doma  could  also  be  restored  with  a  CD4--p56  lck  chimera 
that  lacked  the  kinase  domain,  suggesting that p56  Ick may 
have functioned purely as an adapter to cross-link CD4 with 
the  TCR-CD3  complex  (12).  Similarly,  although  CD4 
was first described as an adhesion molecule,  the attlnity of 
its interaction with MHC  class II molecules is very low (8, 
18,  47).  Thus,  CD4  is  more  likely  to  play  a  role  in  the E 
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Figure 6.  The m/hCD4  chimera 
can act as a potent dominant nega- 
tive. m/hCD4 was expressed under 
the  regulation of a TetR/VP16  fu- 
sion  protein  that acts as  a  potent 
transactivator  when bound to the tet  o 
upstream of a TATA box (see  Materi- 
als and Methods for description).  Ex- 
pression is completely turned  off in 
the  presence of 0.1-1  p.M tetracy- 
cfine (LDs0, 0.5  mM). 3A9.V ex- 
presses the endogenous mCD4  and 
the  transactivator  only,  whereas 
3A9.V.DNm/hCD4  was  produced 
by  transfecting  3Ag.V with  m/ 
hCD4.UHD.2neo.  (A)  Data repre- 
sent the  proliferation of the  IL-2- 
dependent  cell  line  CTLL  in  the 
presence  of  supematants derived 
from hybridomas pulsed with  HEL 
48-61  for 24 h  in the presence or 
absence of 1 p,M tetracycline. All respond comparably to HEL 48-63 and immobilized anti-TCR (data not shown). Phenotype seen with HEL 48-61 is 
comparable to that seen with HEL 48-61FF (data not shown). (B) Expression ofmCD4 plus m/hCD4  (anti-mCD4.D1  -  GK1.5), and m/hCD4 only 
(anti-hCD4.D3  -  Q425) is presented as mean fluorescence. Data are representative of  several clones tested in three independent experiments. 
colocalization of a given TCR  with the same MHC  mole- 
cule, rather than as a "classical" adhesion molecule (3, 5). 
Clearly activation of the HEL 48-63-specific T  cell hy- 
bridoma used here, 3A9,  was not dependent solely on in- 
teraction of CD4  with  either MHC  class II molecules or 
p56 Ick. However,  when  both  sites of interaction were  al- 
tered, function was completely abrogated. CD4 appears not 
to  be  required solely for  providing the  kinase  activity of 
p56  lck in 3A9 cells; otherwise, the cytoplasmic tail deletion 
alone  would  have  abrogated  function.  Similarly,  CD4  is 
not needed solely for interaction with MHC  class II pro- 
teins  through  its  D1/D2  domains;  otherwise  the  MM4 
mutation  in  the  D2  domain  alone would have  abrogated 
function. Additionally, physical and functional experiments 
presented here  using mCD4  D3/D4  mutants  suggest  that 
these  domains  may represent a  third functionally relevant 
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Figure 7.  Physical  interaction between CD4 mutants and the TCR- 
CD3 complex as determined by FRET. Data are expressed  as the mean of 
three separate experiments +  standard error. GK1.5-FITC  (anti-CD4) 
and F23.1-TRITC (anti-TCR-VI38) (9, 11). 
site of interaction for  CD4.  Whereas  some  loss of CD4- 
TCR  interaction using the D3/D4  mutants was evident in 
FRET  experiments, it was only partial, indicating that the 
D3/D4  domains were responsible for only a portion of the 
interaction.  However,  substitution  mutations  of the  D3/ 
D4 domains abolished the ability of CD4  to restore T  cell 
function.  The  functional  effects  mediated by the  D3/D4 
domains may require a second site of interaction to aid in 
the  colocalization of CD4  with  the TCR.  Thus,  removal 
of either the D1/D2  or cytoplasmic domains would have 
only a marginal effect, but removal of both would abrogate 
function. 
Strikingly, the m/hCD4  mutant acted as a potent domi- 
nant negative in the presence of wild-type CD4.  Since the 
levels of CD4 expression can fall 20-fold with only a mini- 
mal  effect  on  T  cell  function,  these  data  are  surprising. 
Two  explanations present themselves.  First, the  m/hCD4 
mutant may interact either with the wild-type CD4 mole- 
cule  directly,  or  with  an  oligomeric  complex  containing 
CD4,  resulting  in  functional  inactivation.  Structural  and 
mutagenesis studies on CD4 and MHC class II molecules have 
provided, at least in part, a possible basis for the dimerization/ 
oligomerization of these molecules with one another (48- 
51). However, if construction of the m/hCD4  mutant had 
affected its ability to dimerize with CD4  directly, it would 
be unable to inactivate the wild-type molecule and would 
therefore have  no  effect on function.  Alternatively, func- 
tional  interaction  with  MHC  class  II  molecules  and/or 
p56 kk  could  require  participation  of all  CD4  molecules 
within  the  dimer or oligomer. A  single m/hCD4  mutant 
within an  oligomer could result in the inactivation of the 
whole complex. Such a result was recently obtained using a 
CD4  mutant that cannot bind to MHC  class II molecules 
in the T  cell hybridoma 171, which is known to be depen- 
dent  on  this  interaction  (12,  51).  However,  it  should  be 
noted that the 3A9 hybridoma used in the studies described 
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teraction with either MHC  class II molecules or p56 l'k. 
The second possibility is that MHC-TCR  colocalization 
occurs normally with the  chimera,  but signal transduction 
may be affected in a manner that inactivates  the  complex. 
A  functional  parallel  could provide  a  clue  to  the  mecha- 
nism by which the dominant negative phenotype is mani- 
fest.  Substitution ofMHC-bound peptide residues that con- 
tact the TCR  can lead to analog peptides that compete for 
TCR  binding and  antagonize  the  response  to  the  natural 
ligand (for reviews see references 52, 53). Such altered pep- 
tide ligands  can block T  cell stimulation  at concentrations 
similar to the agonist, and are in essence acting as dominant 
negatives.  A  phenotypically similar  effect may occur with 
the m/hCD4 mutant, such that interaction with the TCR- 
CD3 complex could induce an incomplete or negative sig- 
nal.  Incomplete signals can be manifest by phosphorylation 
of some proteins but not others (15-17). 
What  physiological  benefit  might  result  from  CD4/ 
TCR-CD3  interaction? MHC class I- and II-mediated re- 
sponses  are  distinguished  in  several  ways.  First,  epitopes 
presented by class I occur as "single" peptides, whereas those 
bound to class II occur as large nested sets (36, 40, 54). Sec- 
ond, the structures of CD4 and CD8 are completely differ- 
ent, despite the fact that the two molecules perform related 
functions. It is possible that because MHC  class I-restricted 
TCR  only have to recognize a single peptide bound within 
the  MHC  class  I  protein,  an  extracellular  interaction  be- 
tween  CD8  and  the  TCR  is  not  required.  However,  as 
MHC  class II-restricted TCR  recognize a large number of 
peptides  derived  from a  single  epitope  and  these  peptides 
are not entirely within the MHC  protein,  CD4 may have 
evolved to transfer  a  signal through  the  extraceUular  por- 
tion of the TCR  in order to increase the level of tolerance 
to peptide variation. 
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